The University Technology Fund hopes to tap investment funds and development finance institutions to raise additional capital.

Proceeds from the Novo-backed series B round will be used to advance Spruce Biosciences' congenital adrenal hyperplasia candidate into phase 2 trials.

WuXi AppTec has co-led a $98m series D round for China-focused drug developer Canbridge Pharmaceuticals that also featured fellow corporate Tigermed.

The sickle cell disease drug developer, which is backed by Pfizer Ventures and Lundbeckfonden Ventures, has filed for an $86.3m IPO.

KKR's Gamma Biosciences platform has committed $54.1m in financing to a new subsidiary of Univercells, whose existing investors include Takeda.

Fonds de solidarité FTQ has officially invested $5m in the fourth fund of ULB's Theodorus, with Théo Risopoulos named as the first team member of a new Quebec office.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The biopharmaceutical company is providing more than $21m for an investment partnership with Jinsheng Capital with a projected close of approximately $87m.

University of Oxford-founded OMass Therapeutics has extended its series A round to progress a pipeline targeting immunological and genetic disorders.

Ackermans & van Haaren fund Sofinim returned for a $20.6m round that will fund the cancer-analysis software provider's expansion and product development.